These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 23547840)

  • 61. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
    Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
    [TBL] [Abstract][Full Text] [Related]  

  • 63. WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience.
    Valkova V; Vydra J; Markova M; Cerovska E; Vrana M; Marinov I; Cechova H; Cetkovsky P; Vitek A; Salek C
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e145-e151. PubMed ID: 33160932
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia--rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation.
    Liu J; Wang Y; Xu LP; Liu DH; Qin YZ; Chang YJ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):929-36. PubMed ID: 24631740
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
    J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia.
    Barrios M; Jiménez-Velasco A; Román-Gómez J; Madrigal ME; Castillejo JA; Torres A; Heiniger A
    Haematologica; 2003 Jul; 88(7):801-10. PubMed ID: 12857560
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
    Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
    Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ
    Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression].
    Cho YU; Park CJ; Cha CH; Chi HS; Jang S; Kim MJ; Lee KH; Lee JH; Lee JH; Seo JJ; Im HJ
    Korean J Lab Med; 2010 Dec; 30(6):533-9. PubMed ID: 21157135
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of post-transplant minimal residual disease on the clinical outcome of pediatric acute leukemia.
    Umeda K; Iwai A; Kawaguchi K; Mikami M; Nodomi S; Saida S; Hiramatsu H; Heike T; Ohmori K; Adachi S
    Pediatr Transplant; 2017 Jun; 21(4):. PubMed ID: 28370903
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].
    Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
    Araki D; Wood BL; Othus M; Radich JP; Halpern AB; Zhou Y; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
    J Clin Oncol; 2016 Feb; 34(4):329-36. PubMed ID: 26668349
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
    Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
    Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Detecting minimal residual disease status in allogeneic hematopoietic stem cell transplantation of patients with high-risk acute leukemia].
    Shi XL; Tang XW; Wei XA; Zhao BR; Zhou QL; Ye F; Lu YX; Sun XW; Zhu MQ; Shen WH; Qiu HY; Sun AN; Wu DP
    Zhonghua Yi Xue Za Zhi; 2011 Oct; 91(38):2692-6. PubMed ID: 22321979
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
    Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
    PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
    Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
    J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation.
    Bouvier A; Riou J; Thépot S; Sutra Del Galy A; François S; Schmidt A; Orvain C; Estienne MH; Villate A; Luque Paz D; Cottin L; Ribourtout B; Beucher A; Delneste Y; Ifrah N; Ugo V; Hunault-Berger M; Blanchet O
    Leukemia; 2020 May; 34(5):1342-1353. PubMed ID: 31768015
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity.
    Zhao XS; Yan CH; Liu DH; Xu LP; Liu YR; Liu KY; Qin YZ; Wang Y; Huang XJ
    Ann Hematol; 2013 Aug; 92(8):1111-9. PubMed ID: 23680867
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chimerism evaluation in measurable residual disease-suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
    Semchenkova A; Brilliantova V; Shelikhova L; Zhogov V; Illarionova O; Mikhailova E; Raykina E; Skorobogatova E; Novichkova G; Maschan A; Maschan M; Popov A
    Cytometry B Clin Cytom; 2021 Sep; 100(5):568-573. PubMed ID: 33369016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.